Kestra Private Wealth Services LLC Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Kestra Private Wealth Services LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 18.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,645 shares of the biopharmaceutical company’s stock after buying an additional 7,257 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Gilead Sciences were worth $3,779,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in GILD. Clearbridge Investments LLC grew its holdings in Gilead Sciences by 179.0% during the 3rd quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock valued at $340,526,000 after buying an additional 2,915,141 shares in the last quarter. abrdn plc grew its holdings in Gilead Sciences by 89.0% during the 4th quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock valued at $304,930,000 after buying an additional 1,772,887 shares in the last quarter. International Assets Investment Management LLC purchased a new position in Gilead Sciences during the 4th quarter valued at approximately $133,584,000. AEGON ASSET MANAGEMENT UK Plc purchased a new position in shares of Gilead Sciences in the 4th quarter worth approximately $63,971,000. Finally, Bailard Inc. boosted its holdings in shares of Gilead Sciences by 9,100.7% in the 3rd quarter. Bailard Inc. now owns 722,345 shares of the biopharmaceutical company’s stock worth $54,133,000 after purchasing an additional 714,494 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.29% of the stock is owned by company insiders.

Gilead Sciences Trading Down 1.1 %

GILD opened at $65.20 on Wednesday. The firm has a market cap of $81.18 billion, a price-to-earnings ratio of 181.11, a PEG ratio of 1.30 and a beta of 0.19. The company has a current ratio of 0.98, a quick ratio of 0.72 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 12 month low of $64.63 and a 12 month high of $87.86. The stock has a fifty day moving average price of $71.03 and a 200-day moving average price of $76.08.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.37 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 3.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.72%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Analyst Ratings Changes

A number of brokerages have recently commented on GILD. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday. Cantor Fitzgerald decreased their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Oppenheimer reissued an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research note on Friday, April 19th. Mizuho decreased their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Finally, UBS Group decreased their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $83.60.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.